Harbin Gloria Pharmaceuticals
HARBIN GLORIA PHARMACEUTICALS Co., LTD engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. Its products include cardiovascular and cerebrovascular, musculoskeletal, vitamins, electrolyte, diabetes-lowering, analgesics, digestive system and metabolism, anti-infective, and anti-tumor drugs. Harbin Gloria Pharmaceuticals Co., Ltd w… Read more
Harbin Gloria Pharmaceuticals (002437) - Total Assets
Latest total assets as of September 2025: CN¥3.03 Billion CNY
Based on the latest financial reports, Harbin Gloria Pharmaceuticals (002437) holds total assets worth CN¥3.03 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Harbin Gloria Pharmaceuticals - Total Assets Trend (2007–2024)
This chart illustrates how Harbin Gloria Pharmaceuticals’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Harbin Gloria Pharmaceuticals - Asset Composition Analysis
Current Asset Composition (December 2024)
Harbin Gloria Pharmaceuticals's total assets of CN¥3.03 Billion consist of 31.1% current assets and 69.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 17.1% |
| Accounts Receivable | CN¥147.49 Million | 5.2% |
| Inventory | CN¥188.67 Million | 6.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥181.11 Million | 6.4% |
| Goodwill | CN¥369.03 Million | 13.1% |
Asset Composition Trend (2007–2024)
This chart illustrates how Harbin Gloria Pharmaceuticals's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Harbin Gloria Pharmaceuticals's current assets represent 31.1% of total assets in 2024, a decrease from 52.3% in 2007.
- Cash Position: Cash and equivalents constituted 17.1% of total assets in 2024, down from 19.2% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 8.0% in 2007.
- Asset Diversification: The largest asset category is goodwill at 13.1% of total assets.
Harbin Gloria Pharmaceuticals Competitors by Total Assets
Key competitors of Harbin Gloria Pharmaceuticals based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Harbin Gloria Pharmaceuticals - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Harbin Gloria Pharmaceuticals generates 0.86x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Harbin Gloria Pharmaceuticals generates $8.24 in net profit.
Harbin Gloria Pharmaceuticals - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.39 | 1.00 | 0.70 |
| Quick Ratio | 1.21 | 0.78 | 0.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥323.26 Million | CN¥ -1.43 Million | CN¥ -755.39 Million |
Harbin Gloria Pharmaceuticals - Advanced Valuation Insights
This section examines the relationship between Harbin Gloria Pharmaceuticals's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.45 |
| Latest Market Cap to Assets Ratio | 0.32 |
| Asset Growth Rate (YoY) | -10.4% |
| Total Assets | CN¥2.83 Billion |
| Market Capitalization | $893.29 Million USD |
Valuation Analysis
Below Book Valuation: The market values Harbin Gloria Pharmaceuticals's assets below their book value (0.32 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Harbin Gloria Pharmaceuticals's assets decreased by 10.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Harbin Gloria Pharmaceuticals (2007–2024)
The table below shows the annual total assets of Harbin Gloria Pharmaceuticals from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.83 Billion | -10.38% |
| 2023-12-31 | CN¥3.15 Billion | -22.62% |
| 2022-12-31 | CN¥4.07 Billion | -13.23% |
| 2021-12-31 | CN¥4.70 Billion | +3.96% |
| 2020-12-31 | CN¥4.52 Billion | -29.52% |
| 2019-12-31 | CN¥6.41 Billion | -32.39% |
| 2018-12-31 | CN¥9.48 Billion | +4.56% |
| 2017-12-31 | CN¥9.06 Billion | +4.59% |
| 2016-12-31 | CN¥8.67 Billion | +4.19% |
| 2015-12-31 | CN¥8.32 Billion | +68.99% |
| 2014-12-31 | CN¥4.92 Billion | +67.26% |
| 2013-12-31 | CN¥2.94 Billion | +14.75% |
| 2012-12-31 | CN¥2.56 Billion | +10.91% |
| 2011-12-31 | CN¥2.31 Billion | +5.37% |
| 2010-12-31 | CN¥2.19 Billion | +395.95% |
| 2009-12-31 | CN¥442.48 Million | +58.47% |
| 2008-12-31 | CN¥279.21 Million | +29.56% |
| 2007-12-31 | CN¥215.51 Million | -- |